Early Treatment Shows Lower Risk to Secondary Progressive MS
All therapies best placebo, prospective study shows by Judy George, Contributing Writer, MedPage TodayJanuary 15, 2019 Multiple sclerosis (MS) patients treated initially…
Can MS Treatment Be Stopped?
Pendulum keeps swinging on risks from drug discontinuation by Judy George, Contributing Writer, MedPage Today March 04, 2019 DALLAS —…
Stuart Schlossman
Scientists spot warning signs for multiple sclerosis
December 27, 2018 The presence of certain levels of a molecule called acrolein in the human body could be an…
Stuart Schlossman
Video: A prediction for the Future of MS Therapeutics [2019]
In this video Aaron Boster, MD, predicts the future, of the MS therapeutic landscape! If you’d like to hear his…
Stuart Schlossman
Pretreating Ocrevus Patients with Multiple Antihistamines and Liquids Lowers Infusion Reactions by 60%, Study Reports
December 18, 2018 Pretreating multiple sclerosis patients with antihistamines more extensively and with hydration can significantly reduce — by 60% — the likelihood…
Stuart Schlossman
Cladribine (also known as Mavenclad™)
Experimental Medications: Administered Orally Company: Merck Oral medication taken for a maximum of 20 days over two years Being studied…
Stuart Schlossman
THE SCIENCE OF MS IS STILL UNDER CONSTRUCTION
We’re breaking down the science behind the condition to reconstruct a new understanding of MS that may build a better…
Stuart Schlossman
Australia MS News: Expensive MS drug (Mavenclad) to be on PBS next year
A drug used to treat people with multiple sclerosis has been added to the Pharmaceutical Benefits Scheme. www.9news.com.au · Dec…
Stuart Schlossman
Shots, Infusions, or Pills for Your MS?
DECEMBER 21, 2018 BY ED TOBIAS There are more than a dozen disease-modifying therapies available to treat MS. Some are…
Stuart Schlossman
Ocrevus Now Available Through NHS Scotland to Treat RRMS
Dec 12, 2018 Ocrevus (ocrelizumab, by Genentech) is now available through the National Health System (NHS) of Scotland to treat patients with…
Stuart Schlossman
